DexCom (DXCM) is moving higher as investors react to the company’s first-quarter 2026 earnings update released April 30, 2026. The quarter showed stronger profitability and operating leverage alongside solid top-line growth, and the company raised key full-year margin targets—an important signal for a stock that has been sensitive to incremental changes in profitability expectations.

DexCom reported Q1 2026 revenue of $1.192 billion, up from $1.036 billion a year earlier (+15% reported). Profitability improved sharply: GAAP operating income was $255.3 million (21.4% margin) versus $133.7 million (12.9% margin) in the year-ago quarter, while GAAP net income was $199.5 million, or $0.51 per diluted share.

For full-year 2026, DexCom reiterated revenue guidance of $5.16–$5.25 billion (about 11%–13% growth) while raising profitability targets. The company increased its non-GAAP operating margin outlook to approximately 23%–23.5% and raised adjusted EBITDA margin guidance to approximately 31%–31.5%, reinforcing the market’s view that operational improvement is continuing into the rest of 2026.

Operationally, DexCom highlighted expanded U.S. launch activity for the Dexcom G7 15 Day CGM and continued development of its Stelo platform features. Investors are also focused on payer-access momentum discussed around the quarter, as broader coverage can expand adoption—especially in large type 2 populations not on insulin—supporting the longer-term growth narrative beyond a single quarter’s results.